This article is a commentary on:
SPTBN5, Encoding the βV-Spectrin Protein, Leads to a Syndrome of Intellectual Disability, Developmental Delay, and Seizures
Danique Beijer
Stephan L. Züchner- Dr. John T. Macdonald Foundation, Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, Miami, FL, United States
A Commentary on
SPTBN5, encoding the βV-spectrin protein, leads to a syndrome of intellectual disability, developmental delay, and seizures
by Khan, A., Bruno, L. P., Alomar F., Umair, M., Pinto, A. M., Khan, A. A., Khan, A., Saima, Fabbiani, A., Zguro, K., Furini, S., Mencarelli, M. A., Renieri, A., Resciniti, S., Peña-Guerra, K. A., Guzmán-Vega, F. J., Arold, S. T., Ariani, F., Khan, S. A. (2022). Front. Mol. Neurosci. 15, 877258. doi: 10.3389/fnmol.2022.877258
The spectrin-cytoskeleton, consisting of combinations of alpha-spectrin and beta-spectrin subunits, is essential for preserving the integrity and mechanical characteristics of the cell membrane. In the nervous system it is critical for the correct assembly and maintenance of neuronal excitable domains including the axon initial segment and the nodes of Ranvier (Liu and Rasband, 2019).
Dysfunction of the spectrin-cytoskeleton and their associated proteins has been implicated in several human diseases, but with a particular enrichment for neurodevelopmental and neurodegenerative diseases (Liu and Rasband, 2019). The non-erythroid variants of spectrin proteins (SPTAN1, SPTBN1,2,4 and 5) have now all been implicated in neurological diseases with either dominant or recessive inheritance, sometimes both (Ikeda et al., 2006; Lise et al., 2012; Knierim et al., 2017; Syrbe et al., 2017; Wang et al., 2018; Beijer et al., 2019; Rosenfeld et al., 2021; Khan et al., 2022; Van De Vondel et al., 2022).
One of the main challenges within the group of the spectrin gene mutations is the interpretation of candidate variants. All non-erythroid spectrin protein can be considered large containing at least 2,300 residues. Therefore, despite their general genetic constraint, spectrin genes still accumulate a large number of variants, of which only a small number will be causative for disease. In addition, the phenotype associated with spectrin mutations is rapidly expanding, which poses difficulties for the interpretation of these variants in the clinical context, resulting in many variants of unknown significance (VUS) (Savarese et al., 2020).
We read with great interest the newest paper in this field, which implicates four different heterozygous de novo variants in SPTBN5 (His89Pro, Tyr311*, Asn2937Tyr, Glu3262Lys) as the disease cause in patients with a combination of intellectual disability, developmental delay and seizures (Khan et al., 2022). The study is appealing in the context of other spectrin-related diseases but raises some concerns that need to be addressed. In fact, there are two main limitations to this study, which combined raise the question of the true pathogenicity of the four variants implicated to cause the neurodevelopmental phenotype.
The first limitation is the general approach to filtering of the whole-exome sequencing (WES) where all variants with a minor allele frequency (MAF) <1% in the Exome Variant Server, GnomAD and 1000 Genomes were considered. While not necessarily wrong, even under an autosomal dominant hypothesis, further consideration was needed, when a heterozygous allele count of 24 and 1,042 (and 4 homozygous counts) was observed for the variants Glu3262Lys and Asn2937Tyr, respectively. These heterozygous allele counts are generally considered too high for fully penetrant dominant and rare disorders, especially considering the early-onset and severity of the disease described (Pipis et al., 2019). It is further surprising that these two variants would be observed de novo in the study, when they have already been observed not unfrequently in the population.
The second limitation of the study is the lack of a description of genetic testing performed to confirm the parentage of the affected patients. Especially for the variants with the increased allele count, the presence in the general population strongly supports a dominant inheritance rather than a de novo inheritance. However, even for the two variants His89Pro and Tyr311*, for which the heterozygous allele count in gnomAD could be supportive of pathogenicity (allele counts of 1 and 2 respectively), the confirmation of parentage is essential to conclude a de novo inheritance. It is finally unclear how a de novo variant would occur in two siblings in two of the presented families. Genetic mosaicism is a possibility, but was not mentioned by Khan et al., and appears unlikely to be present in two out of four reported families. Finally, the paper at the end of the Introduction mistakenly states a homozygous occurrence of these four variants in the patients, which is not supported by the provided figure and a later statement in the Discussion.
Overall, an association between SPTBN5 and a neurodevelopmental phenotype would not be unexpected and would fit well with the overall importance of the spectrin-cytoskeleton in the nervous system. However, further evidence is needed for SPTBN5 to join the growing list of monogenic disorders caused by spectrin genes.
Author contributions
DB drafted the initial manuscript. DB and SZ revised the manuscript. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Beijer, D., Deconinck, T., De Bleecker, J. L., Dotti, M. T., Malandrini, A., Urtizberea, J. A., et al. (2019). Nonsense mutations in alpha-II spectrin in three families with juvenile onset hereditary motor neuropathy. Brain 142, 2605–2616. doi: 10.1093/brain/awz216
Ikeda, Y., Dick, K. A., Weatherspoon, M. R., Gincel, D., Armbrust, K. R., Dalton, J. C., et al. (2006). Spectrin mutations cause spinocerebellar ataxia type 5. Nat. Genet. 38, 184–190. doi: 10.1038/ng1728
Khan, A., Bruno, L. P., Alomar, F., Umair, M., Pinto, A. M., Khan, A. A., et al. (2022). SPTBN5, encoding the betaV-spectrin protein, leads to a syndrome of intellectual disability, developmental delay, and seizures. Front. Mol. Neurosci. 15, 877258. doi: 10.3389/fnmol.2022.877258
Knierim, E., Gill, E., Seifert, F., Morales-Gonzalez, S., Unudurthi, S. D., Hund, T. J., et al. (2017). A recessive mutation in beta-IV-spectrin (SPTBN4) associates with congenital myopathy, neuropathy, and central deafness. Hum. Genet. 136, 903–910. doi: 10.1007/s00439-017-1814-7
Lise, S., Clarkson, Y., Perkins, E., Kwasniewska, A., Sadighi Akha, E., Schnekenberg, R. P., et al. (2012). Recessive mutations in SPTBN2 implicate beta-III spectrin in both cognitive and motor development. PLoS Genet. 8, e1003074. doi: 10.1371/journal.pgen.1003074
Liu, C. H., and Rasband, M. N. (2019). Axonal spectrins: nanoscale organization, functional domains and spectrinopathies. Front. Cell Neurosci. 13, 234. doi: 10.3389/fncel.2019.00234
Pipis, M., Rossor, A. M., Laura, M., and Reilly, M. M. (2019). Next-generation sequencing in Charcot-Marie-Tooth disease: opportunities and challenges. Nat. Rev. Neurol. 15, 644–656. doi: 10.1038/s41582-019-0254-5
Rosenfeld, J. A., Xiao, R., Bekheirnia, M. R., Kanani, F., Parker, M. J., Koenig, M. K., et al. (2021). Heterozygous variants in SPTBN1 cause intellectual disability and autism. Am. J. Med. Genet. A 185, 2037–2045. doi: 10.1002/ajmg.a.62201
Savarese, M., Valipakka, S., Johari, M., Hackman, P., and Udd, B. (2020). Is gene-size an issue for the diagnosis of skeletal muscle disorders? J. Neuromuscul. Dis. 7, 203–216. doi: 10.3233/JND-190459
Syrbe, S., Harms, F. L., Parrini, E., Montomoli, M., Mutze, U., Helbig, K. L., et al. (2017). Delineating SPTAN1 associated phenotypes: from isolated epilepsy to encephalopathy with progressive brain atrophy. Brain 140, 2322–2336. doi: 10.1093/brain/awx195
Van De Vondel, L., De Winter, J., Beijer, D., Coarelli, G., Wayand, M., Palvadeau, R., et al. (2022). De novo and dominantly inherited SPTAN1 mutations cause spastic paraplegia and cerebellar ataxia. Mov. Disord. 37, 1175–1186. doi: 10.1002/mds.28959
Keywords: spectrin (α/β), monogenic disease, next generation sequencing (NGS), neurodevelopmental disorders, genetic data analysis, spectrin cytoskeleton
Citation: Beijer D and Züchner SL (2022) Commentary: SPTBN5, encoding the βV-spectrin protein, leads to a syndrome of intellectual disability, developmental delay, and seizures. Front. Mol. Neurosci. 15:1011856. doi: 10.3389/fnmol.2022.1011856
Received: 04 August 2022; Accepted: 18 August 2022;
Published: 02 September 2022.
Edited by:
Maren Engelhardt, Johannes Kepler University of Linz, AustriaReviewed by:
Yoichi Araki, Johns Hopkins University, United StatesCopyright © 2022 Beijer and Züchner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Danique Beijer, ZHhiMTI2NyYjeDAwMDQwO21lZC5taWFtaS5lZHU=